Grifols, S.A. Sponsored ADR Class B Stock News

NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF) (NASDAQ: GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the “Board”). In the letter, Mason highlights numerous corporate governance failures that have resulted in ...

Spanish drugmaker Grifols said on Thursday it was on track to meet its targets for the year after its net profit fell 7.5% in the third quarter from the same period a year ago.

Grifols, S.A. is undervalued and worth more than its current market valuation, making it a strong buy even without a potential Brookfield buyout. The company leads the global plasma market, with significant growth in immunoglobulin and albumin segments, and has a robust infrastructure and geographical reach. Despite facing competition and emerging technologies, Grifols' fundamentals are solid, ...

Spanish drugmaker Grifols plans to invest 360 million euros ($401.98 million) to build a new industrial plant in Barcelona for its engineering department, newspaper El Economista said on Monday, citing unidentified company sources.

BARCELONA, Spain--(BUSINESS WIRE)--Significant Grifols shareholders fill a vacant board seat, appointing pharma leader Paul Herendeen to drive value and improve governance.

CAIRO--(BUSINESS WIRE)--Orange Business is pleased to announce the successful completion of the first phase of a new data center and communications infrastructure for Grifols Egypt for its Plasma Derivatives (GEPD) facility in the Medical City within the New Administrative Capital. The partnership involves delivering co-location services through the ACUD (Administrative Capital for Urban Develo...

Canadian fund Brookfield is in talks with banks to raise funds for its possible takeover bid for beleaguered Spanish drugmaker Grifols , two people familiar with the matter said on Wednesday.

Spanish pharmaceutical company Grifols said on Tuesday it had revised its financial records between 2020 and 2023 lower by 457 million euros ($494 million) to adjust the value of its stake in Chinese company Shanghai RAAS.